Targeting Mechanisms Driving ErbB2 Activation in Subsets of CRPC
Abstract
Our overall hypothesis is that the ErbB2 pathway is driving a subset of advanced PCa, and that these patients would respond to a therapy that effectively suppresses ErbB2 signaling. Our corresponding overall objective is to generate the preclinical data needed to support a biomarker driven clinical trial of an ErbB2 inhibitor in advanced CRPC. To achieve this objective, Aim 1 will first determine whether the d16ErbB2 splice variant activates a distinct downstream pathway. Aim 2 will in parallel identify mechanisms of intrinsic and acquired resistance to ErbB2 inhibitors, and Aim 3 will translate the results into clinical samples to identify biomarkers that may be predictive of responses to ErbB2 targeted therapies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2020
- Accession Number
- AD1106346
Entities
People
- Steven P Balk